Clinical Trials in the North Cancer Alliance
Clinical Trials in the North Cancer Alliance
Clinical trials open to recruitment or in set-up in North Cancer Alliance Health Boards are shown within the below table for tumour specific areas. Clinical trial information is provided by NRS Cancer Research Network – North & East from data available on EDGE.
| Trial | Description | Centre |
Breast Cancer Clinical Trials |
||
| ATNEC | Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy |
ARI Raigmore |
| Characterisation of breast tumours by Fast Field Cycling MRI | Characterisation of breast tumours by Fast Field Cycling MRI | ARI |
| CloseHER2 Home | CloseHER2 Home - A feasibility study of a community pharmacy-led pathway for the administration of subcutaneous trastuzumab for HER2 positive breast cancer patients | Ninewells |
| CONCERT | Inflammatory and Neural Correlates of Chemotherapy-Induced Cognitive Impairment: A pilot study | ARI |
| DESTINY BREAST - RESPOND | A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ unresectable and/or metastatic breast cancer | Raigmore |
|
Defining the role of adipocytes in cancer and metabolic disorders |
Defining the role of adipocytes in cancer and metabolic disorders | ARI |
| EndoNET | Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women | ARI |
|
Fast field cycling MRI |
Characterisation of breast tumours by Fast Field Cycling MRI | ARI |
|
HER2 RADICAL |
The HER2-RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer | ARI |
| OPTIMA | Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis |
ARI Ninewells |
| POETIC-A | PreOperative Endocrine Therapy for Individualised Care with Abemaciclib |
ARI |
| SMALL | Open surgery versus minimally invasive vacuum-assisted excision for small screen-detected breast cancer – a phase III randomised multi-centre trial |
ARI |
| TARGIT-X | Extended follow up of the TARGIT-A trial |
Ninewells |
| The MARECA study | National study of management of breast cancer locoregional recurrence and oncological outcome |
ARI Ninewells |
Colorectal Cancer Clinical Trials |
||
| ARIEL | A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) |
ARI |
| ARTEMIS | Augmenting RadioTherapy in REctal Cancer to Minimise Invasive Surgery |
ARI |
| CORINTH |
Phase 1b/II Trial of Checkpoint Inhibitor (Pembrolizumab an Anti PD-1 Antibody) Plus Standard IMRT in HPV Induced Stage III Squamous Cell Carcinoma of Anus |
ARI |
| Fast Field Cycling MRI and Microbiota in Rectal Cancer | Analysing if chemoradiotherapy treatment in rectal cancer can be predicted by Fast Field Cycling imaging and Microbiota sampling. The Microbrect-FFC study |
ARI |
| FOxTROT Platform | Personalising neo-adjuvant Chemotherapy in Locally advanced but operable colon cancer. A randomised trial programme. |
Ninewells |
| GARNET | A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors |
ARI |
| PELICAN-23 | Exploiting the gut microbiota and its metabolites in pelvic cancer to improve patient outcomes |
ARI |
| SEAMARK | Randomized Phase 2 Trial of Encorafenib and Cetuximab plus Pembrolizumab versus Pembrolizumab Alone in Participants with Previously Untreated BRAF V600E-mutant, MSI-H/dMMR Metastatic Colorectal Cancer. |
ARI |
| SOCCS3 | Scottish Colorectal Cancer Genetic Susceptibility Study 3 |
Ninewells |
| STAR TREC | Can we Save the rectum by watchful waiting or TransAnal surgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer? |
Ninewells |
|
The Microbrect- FFC Study |
Analysing if chemoradiotherapy treatment in rectal cancer can be predicted by Fast Field Cycling imaging and Microbiota sampling. |
ARI |
|
The SCOTTY Study |
Whole genome sequencing study of young colon cancer patients and their parents | ARI |
| TRACC C | Tracking mutations in cell free tumour DNA to predict Relapse in Early ColorectalCancer | ARI |
Gynaecological Cancer Clinical Trials |
||
Cervical |
||
| COMICE | A randomized double blind placebo controlled Phase II clinical trial of Cediranib and Olaparib maintenance in advanced recurrent Cervical Cancer | ARI |
Endometrial |
||
| ELECTRA: Targeted Molecular Testing in Endometrial Carcinoma | "ELECTRA: Expanding the Laboratory diagnosis of Endometrial Carcinoma through Targeted molecular testing based on Risk Assessment - A Prospective Multi-Centre Observational Study Comparing Different Testing Algorithms" |
Raigmore |
Ovarian |
||
| DOCS | Dundee Ovarian Cancer Drug Resistance Study | Ninewells |
| PROTECTOR | Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal | ARI Ninewells |
Haematological Clinical Trials |
||
Leukaemia |
||
| ALLTogether1 | ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL) |
RACH |
| CiproPAL | CiproPAL (Ciprofloxacin Prophylaxis in Acute Leukaemia): A randomised trial to assess the use of ciprofloxacin prophylaxis to prevent bacterial infection in children treated on the induction phase of the ALLTogether1 treatment protocol |
RACH |
| STATIC | A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL) |
ARI |
| The UK National Registry of Chronic Myeloid Leukaemia | The UK National Registry of Chronic Myeloid Leukaemia |
ARI Raigmore |
| VICTOR | Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: A Molecularly Guided Phase 2 Study |
ARI |
| VIVO Biobank | Research Tissue Bank |
RACH |
Lymphoma |
||
| BGB-3111-LTE1 | An Open-label, Multi-center, Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Patients with B-cell Malignancies | ARI |
| FRONTMIND | A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | ARI |
|
PETReA |
Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma | ARI |
|
RADAR |
A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT inpatients with previously untreated stage IA/IIA Hodgkin lymphoma | ARI |
Myelodysplastic Syndrome (MDS) |
||
| AMMO | A randomised phase 2 study of ASTX727 versus best supportive care in MDS/MPN Overlap Syndromes | ARI |
| EUMDS | A prospective, multicentre European Registry for newly diagnosed patients with Myelodysplastic Syndromes (MDS), including acute myeloid leukaemia with 20-30 percent marrow blasts (former RAEB-t), and Chronic Myelomonocytic Leukaemia (CMML). | ARI |
| Phase 3 Study of SY-1425 Plus Azacitidine in RARA-positive Higher-risk MDS | " A Randomized, Double-blind, Placebo-controlled Phase 3 Study of SY-1425 Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, RARA-positive Adult Patients with Higher-risk Myelodysplastic Syndrome" |
Ninewells |
| REPAIR MDS | Repurposed drugs to improve haematological responses in Myelodysplastic Syndromes | ARI |
Myeloma |
||
| FiTNEss (MYELOMA XIV) | Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma: A phase III trial to compare standard and frailty-adjusted induction therapy with ixazomib, lenalidomide and dexamethasone (IRD) and maintenance lenalidomide (R) to lenalidomide plus ixazomib (R+I) |
ARI |
| MonumenTAL-3 | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy |
Ninewells |
|
RADAR |
Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE) | ARI Ninewells Raigmore |
Haemophilia/Blood |
||
| EHL-Registry | Evaluation of Real World Outcomes with Extended half-Life Concentrates for Routine Clinical Use in Haemophilia A and B: UK-EHL Outcome Registry | ARI RACH |
| MITHRIDATE | MITHRIDATE: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapy for high risk polycythemia vera |
ARI Raigmore |
| MOSAICC | "MyelOproliferative neoplasmS: An In-depth Case-Control (MOSAICC) study: A case-control study of patients with Myeloproliferative neoplasms and non-blood relative/friend controls." |
ARI Raigmore
|
|
UKHRR (In set-up) |
The United Kingdom Haemophilia Research Registry |
ARI Ninewells |
| UK-TTP Registry | The United Kingdom Thrombotic Thrombocytopenic Purpura Registry | ARI |
Hepato-Pancreato-Biliary (HBP) Cancer Clinical Trials |
||
Pancreas |
||
| Phase 3 study in patients previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma | "A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With Or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma" |
ARI |
| Precision Panc | Advancing personalised medicine treatment strategies for pancreatic cancer |
ARI |
| PRIMUS 001 | An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation |
ARI |
| SABR-COMET-3 | Phase III Randomized Controlled Trial and Economic Evaluation of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 metastases) cancer: SABR-COMET-3 |
ARI |
|
|
||
Head and Neck Cancer Clinical Trials |
||
| ADEPT DDR | Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer | ARI |
| CompARE Trial, Version 1.0 | Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high risk oropharyngeal cancer | ARI |
| HoT | Hemithyroidectomy or Total-Thyroidectomy in 'low-risk' thyroid cancers | Ninewells |
| LEAP-009 | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) | ARI |
| NG11-2-P1b | A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis in Patients with Head & Neck Cancer | ARI |
| PETNECK 2 | PET-CT guided, symptom-based, patient-initiated surveillance versus clinical follow-up in head and neck cancer | ARI |
| SAVER | Sodium Valproate for Epigenetic Reprogramming in the Management of High Risk Oral Epithelial Dysplasia | ARI |
Lung Cancer Clinical Trials |
||
Non Small Cell Lung Cancer (NSCLC) |
||
| CODEBREAK 202 |
A PHASE 3 MULTICENTER, RANDOMIZED, OPEN LABEL STUDY EVALUATING EFFICACY OF SOTORASIB PLATINUM DOUBLET COMBINATION VERSUS PEMBROLIZUMAB PLATINUM DOUBLET COMBINATION AS A FRONT-LINE THERAPY IN PATIENTS WITH STAGE IV OR ADVANCED STAGE IIIB/C NONSQUAMOUS NON-SMALL CELL LUNG CANCERS, NEGATIVE FOR PD-L1, AND POSITIVE FOR KRAS PG12C |
|
| PACIFIC-9 | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy | Ninewells |
| SUNRAY-01 | A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pemetrexed and Platinum for the First-line Treatment of Participants with KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer |
ARI (in setup) |
Small Cell Lung Cancer (SCLC) |
||
| AVANZAR | Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination with Radiotherapy and Temozolomide in Subjects with Newly Diagnosed Glioblastoma with MGMT methylated and unmethylated promoter status |
ARI (in set-up) |
Lung Cancer Generic |
||
| E2 RADIATE | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe |
ARI |
| LUNGSCOT Pilot | How should Scotland respond to the challenge of lung cancer screening? The LUNGSCOT mixed-methods feasibility study |
ARI / Raigmore |
Mesothelioma |
||
| ASSESS-Meso (TILT) cohort study | A prospective observational cohort study examining the natural history of mesothelioma, exploring potential biomarkers and factors that may predict outcome, as well as providing a resource for future trials within a cohort. | Raigmore |
Skin Cancer Clinical Trials |
||
Melanoma |
||
|
UKKCC Skin Cancer Atlas v1.0 |
UK Keratinocyte Cancer Collaborative - Generating a Molecular Atlas for Skin Cancer | Ninewells |
Upper GI Cancer Clinical Trials |
||
| DS-8201a in participants with HER2+ Cancer after disease progression | A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects with HER2 Positive Metastatic and/or Unresectable Gastric or Gastro Esophageal Junction (GEJ) Adenocarcinoma Subjects who have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) | Ninewells |
| DZB-CS-202: phase 1b/2 HER2-negative gastric adenocarcinoma study | A Phase 1b/2 study of derazantinib as second-line monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2- negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03) |
|
| ELEVATE | Temozolomide + nivolumab in MGMT deficient oesophagogastric cancer | Ninewells |
| LEAP-014 | A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK3475) + Lenvatinib (E7080/MK-7902) with Chemotherapy-Induction Followed by Pembrolizumab + Lenvatinib Compared with Chemotherapy as First-line Intervention in Participants with Metastatic Esophageal Carcinoma | Ninewells |
| Pembrolizumab & Chemoradiation in Oesophageal Carcinoma Participants | A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) | ARI |
| Ph1b/3 Bemarituzumab in Advanced Gastric Gastroesophageal Cancer (FORTITUDE-102) | "A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Cancer With FGFR2b Overexpression" |
Ninewells |
| PLATFORM | Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial | Ninewells |
| REGAL | Capturing trastuzumab Resistance in Gastroesophageal Adenocarcinoma by Liquid biopsy | Ninewells |
| TROPION-PanTumor 03 | A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours (TROPION-PanTumor03) |
Ninewells |
Urological Cancer Clinical Trials |
||
Bladder Cancer |
||
| ISABELLA | InveStigAting Bladder fiELd-cycLing imAging (ISABELLA) | ARI |
| KEYNOTE 676 | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette- Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) that is Persistent or Recurrent Following BCG Induction | Raigmore |
| Rad-IO | A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer | ARI |
Prostate Cancer |
||
| AMPLITUDE | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | Raigmore |
| E2 RADIATE | EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | ARI |
| EvoPAR-Prostate 01 | A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer |
ARI (in setup) |
| PEARLS study | A Phase II/III trial of Primary radiotherapy for Androgen sensitive Prostate cancer patients with Lymph nodes | ARI |
| PIVOTALboost | A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost |
ARI Raigmore |
| UK Genetic Prostate Cancer Study | UK Genetic Prostate Cancer Study | Ninewells |
Renal Cancer |
||
| UMBRELLA | A SIOP Renal Tumours Study Group prospective study | RACH |
Testicular Cancer |
||
| UKP3BEP | A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours | ARI |
| MULTIPLE | ||
| Extension Study-Participants-Advanced Tumors in Pembrolizumab trials |
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. | ARI |
| SACHA International | Secured Access to innovative medicines for CHildren, adolescents and young adults with cAncer (SACHA) | RACH |